^
Association details:
Biomarker:STING mutation
Cancer:Colon Cancer
Drug:CS-1010 (STING agonist)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Discovery of novel STING agonists with robust anti-tumor activity

Published date:
05/15/2020
Excerpt:
Several lead compounds CS-1018, CS-1020 and CS-1010 activate mouse and human STING variants in vitro with much better potency than natural ligand cGAMP and reference compound X...The antitumor activity of compound CS-1020 and CS-1010 was also demonstrated in MC38 mouse model. When CS-1020 was dosed at 5 ug or 25 ug, complete responses were observed in 63% or 88% of mice respectively. In the case of CS-1010, the dose of 5 ug provides complete responses in 100% of treated mice....We have identified several STING agonists, which demonstrated better cellular potency to mouse and human STING alleles compared to natural ligand cGAMP and reference compound.